Pablo Vivas to Cell Movement
This is a "connection" page, showing publications Pablo Vivas has written about Cell Movement.
Connection Strength
0.801
-
Villarreal-Garc?a V, Estupi?an-Jim?nez JR, Gonzalez-Villasana V, Vivas-Mej?a PE, Flores-Col?n M, Ancira-Moreno IE, Zapata-Mor?n PA, Altamirano-Torres C, V?zquez-Guillen JM, Rodr?guez-Padilla C, Bayraktar R, Rashed MH, Ivan C, Lopez-Berestein G, Res?ndez-P?rez D. Inhibition of microRNA-660-5p decreases breast cancer progression through direct targeting of TMEM41B. Hereditas. 2024 Dec 21; 161(1):53.
Score: 0.685
-
Echevarr?a-Vargas IM, Valiyeva F, Vivas-Mej?a PE. Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLoS One. 2014; 9(5):e97094.
Score: 0.082
-
Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Shazhad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK. Src activation by ?-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013; 4:1403.
Score: 0.019
-
Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88.
Score: 0.016